In 2014, the U.S. Food and Drug Administration (FDA) approved pembrolizumab and nivolumab as the first anti-PD-1 (CD279) directed monoclonal antibodies (Figure 1) for use in advanced cancers, namely in advanced or metastatic melanoma. Here, PDCD1 is linked to metastatic melanoma.